Anubha Seth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anubha Seth has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aashish Manglik
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA
1 shared publication Alejandro Soto-Gutierrez
1 shared publication- Allan I. Basbaum
Department of Anatomy, University of California, San Francisco, San Francisco, USA
1 shared publication - Bethlehem Bekele
Department of Pharmacology, Yale University
1 shared publication - Brian K. Shoichet
Department of Pharmaceutical Chemistry, University of California, San Francisco
1 shared publication Bryan L. Roth
Department of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Elsevier in EBioMedicine
- Vol. 132
Liver disease reveals KIF12 as a regulator of mitochondria, lysosome and cilia localisation in human cholangiocytes
- 11 September 2026
- Published by Elsevier in EBioMedicine
- Vol. 132
Open AccessLiver disease reveals KIF12 as a regulator of mitochondria, lysosome and cilia localisation in human cholangiocytes
- Open Access
Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter
SUMMARY: The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has an unusual anti-depressant profile and stabilizes the inward-open conformation. Unfortunately, ibogaine is promiscuous and cardiotoxic, limiting understanding of inward-open state ligands. We computationally docked over 200 million small molecules against the ibogaine stabilized inward-open state of SERT. Thirty-six top-ranking compounds were synthesized and thirteen inhibited with potencies ranging from 29 to 5000 nM. Structure-based optimization led to two novel inhibitors with Ki values down to 3 nM. The new molecules stabilized an outward-closed state of the transporter and had little activity against off-targets. A cryo-EM structure of one of these bound to SERT confirmed the predicted geometry. In mouse behavioral assays, both had anxiolytic and anti-depressant activity, with potencies up to 200 better than fluoxetine.
Open AccessStructure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter
SUMMARY: The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has an unusual anti-depressant profile and stabilizes the inward-open conformation. Unfortunately, ibogaine is promiscuous and cardiotoxic, limiting understanding of inward-open state ligands. We computationally docked over 200 million small molecules against the ibogaine stabilized inward-open state of SERT. Thirty-six top-ranking compounds were synthesized and thirteen inhibited with potencies ranging from 29 to 5000 nM. Structure-based optimization led to two novel inhibitors with Ki values down to 3 nM. The new molecules stabilized an outward-closed state of the transporter and had little activity against off-targets. A cryo-EM structure of one of these bound to SERT confirmed the predicted geometry. In mouse behavioral assays, both had anxiolytic and anti-depressant activity, with potencies up to 200 better than fluoxetine.